Biotechnology in the United Kingdom

Date: November 25, 2016
Pages: 34
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BACB3F1D49BEN
Leaflet:

Download PDF Leaflet

Biotechnology in the United Kingdom
SUMMARY

Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United Kingdom
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United Kingdom
  • Leading company profiles reveal details of key biotechnology market players' global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom biotechnology market with five year forecasts
REASONS TO BUY
  • What was the size of the United Kingdom biotechnology market by value in 2016?
  • What will be the size of the United Kingdom biotechnology market in 2021?
  • What factors are affecting the strength of competition in the United Kingdom biotechnology market?
  • How has the market performed over the last five years?
  • What are the main segments that make up the United Kingdom's biotechnology market?
KEY HIGHLIGHTS

The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

The UK biotechnology market is expected to generate total revenues of $10.4bn in 2016, representing a compound annual growth rate (CAGR) of 5.7% between 2012 and 2016.

The Medical/Healthcare segment is expected to be the market's most lucrative in 2016, with total revenues of $6.9bn, equivalent to 66% of the market's overall value.

In 2015 the investment into UK biotechnology reached a 10 year high, helping narrow the funding gap to the United States having previously lost highly promising biotech start-ups to New York.
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
AstraZeneca PLC
GE Healthcare
Novartis AG
Sanofi SA
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: United Kingdom biotechnology industry value: $ million, 2012-16(e)
Table 2: United Kingdom biotechnology industry category segmentation: $ million, 2016(e)
Table 3: United Kingdom biotechnology industry geography segmentation: $ billion, 2016(e)
Table 4: United Kingdom biotechnology industry value forecast: $ million, 2016-21
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: GE Healthcare: key facts
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sanofi SA: key facts
Table 13: Sanofi SA: key financials ($)
Table 14: Sanofi SA: key financials (€)
Table 15: Sanofi SA: key financial ratios
Table 16: United Kingdom size of population (million), 2012-16
Table 17: United Kingdom gdp (constant 2005 prices, $ billion), 2012-16
Table 18: United Kingdom gdp (current prices, $ billion), 2012-16
Table 19: United Kingdom inflation, 2012-16
Table 20: United Kingdom consumer price index (absolute), 2012-16
Table 21: United Kingdom exchange rate, 2012-16


LIST OF FIGURES

Figure 1: United Kingdom biotechnology industry value: $ million, 2012-16(e)
Figure 2: United Kingdom biotechnology industry category segmentation: % share, by value, 2016(e)
Figure 3: United Kingdom biotechnology industry geography segmentation: % share, by value, 2016(e)
Figure 4: United Kingdom biotechnology industry value forecast: $ million, 2016-21
Figure 5: Forces driving competition in the biotechnology industry in the United Kingdom, 2016
Figure 6: Drivers of buyer power in the biotechnology industry in the United Kingdom, 2016
Figure 7: Drivers of supplier power in the biotechnology industry in the United Kingdom, 2016
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in the United Kingdom, 2016
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in the United Kingdom, 2016
Figure 10: Drivers of degree of rivalry in the biotechnology industry in the United Kingdom, 2016
Figure 11: AstraZeneca PLC: revenues and profitability
Figure 12: AstraZeneca PLC: assets and liabilities
Figure 13: Novartis AG: revenues and profitability
Figure 14: Novartis AG: assets and liabilities
Figure 15: Sanofi SA: revenues and profitability
Figure 16: Sanofi SA: assets and liabilities


COMPANIES MENTIONED

AstraZeneca PLC
GE Healthcare
Novartis AG
Sanofi SA
Skip to top


Fragrances in the United Kingdom US$ 350.00 Nov, 2016 · 37 pages
Internet Access in the United Kingdom US$ 350.00 Nov, 2016 · 40 pages
Vinegar United Kingdom US$ 100.00 Mar, 2016 · 10 pages
Dehydrated soup United Kingdom US$ 100.00 Mar, 2016 · 10 pages
Frozen soup United Kingdom US$ 100.00 Mar, 2016 · 10 pages

Ask Your Question

Biotechnology in the United Kingdom
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: